Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase Ⅲ China-centric study, MEASURE 5

著录项

• 来源
  《中华医学杂志（英文版）》 |2020年第21期|2521-2531|共11页
• 作者

  Feng Huang; Yi Wang; Hao-Min Qiu; Brian Porter; Sibylle Haemmerle; Fei Sun; Wei-Guo Wan; Li-Jun Wu; Ling-Li Dong; Xiao Zhang; Tae-Hwan Kim; Raj Sengupta; Ladislav Senolt;

  展开▼
• 作者单位

  Department of Rheumatology Chinese People's Liberation Army General Hospital Beijing 100853 China;

  Novartis Pharmaceuticals Corporation East Hanover N J USA;

  China Novartis Institutes for Biomedical Research Shanghai 201203 China;

  Novartis Pharmaceuticals Corporation East Hanover N J USA;

  Novartis Pharma AG Basel Switzerland;

  Department of Rheumatology Chinese People's Liberation Army General Hospital Beijing 100853 China;

  Department of Rheumatology Huashan Hospital Fudan University Shanghai 200040 China;

  Department of Rheumatology & Immunology People's Hospital of Xinjiang Uygur Autonomous Region Urumqi Xinjiang 830001 China;

  Department of Rheumatology & Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science & Technology Wuhan Hubei 430030 China;

  Department of Rheumatology & Immunology Guangdong General Hospital Guangzhou Guangdong 510000 China;

  Hanyang University Hospital for Rheumatic Diseases Seoul Republic of Korea;

  Royal National Hospital for Rheumatic Disease Upper Borough Walls Bath BA1 1RL UK;

  Institute of Rheumatology Prague Czech Republic;

  展开▼
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词